In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

Jorgensen, who has been CEO since 2017, will remain in the role until a new CEO has been appointed, Novo Nordisk said ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...